From the Aghia Sophia Children's Hospital, Athens University School of Medicine, Athens, Greece.
National Reference Center for Herpesviruses, University Hospital Limoges, France.
Pediatr Infect Dis J. 2019 Feb;38(2):181-188. doi: 10.1097/INF.0000000000002233.
Varicella is a common vaccine-preventable disease that usually presents as a mild disorder but can lead to severe complications. Before the implementation of universal varicella vaccination (UVV) in some European countries, the burden of varicella disease was broadly similar across the region. Despite this, countries adopted heterogeneous varicella vaccination strategies. UVV is currently recommended in 12 European countries. Known barriers to UVV implementation in Europe include (1) a perceived low disease burden and low public health priority; (2) cost-effectiveness and funding availability; (3) concerns related to a shift in varicella disease and incidence of herpes zoster and (4) safety concerns related to measles, mumps, rubella and varicella-associated febrile seizures after the first dose. Countries that implemented UVV experienced decreases in varicella incidence, hospitalizations and complications, showing overall beneficial impact. Alternative strategies targeting susceptible individuals at higher risk of complications have been less effective. This article discusses ways to overcome the barriers to move varicella forward as a truly vaccine preventable disease.
水痘是一种常见的可通过疫苗预防的疾病，通常表现为轻度疾病，但可导致严重并发症。在一些欧洲国家实施普遍水痘疫苗接种（UVV）之前，该地区的水痘疾病负担大致相似。尽管如此，各国仍采用了不同的水痘疫苗接种策略。目前，欧洲有 12 个国家推荐使用 UVV。在欧洲实施 UVV 的已知障碍包括：（1）认为疾病负担低且公共卫生优先级低；（2）成本效益和资金可用性；（3）对水痘疾病和带状疱疹发病率以及（4）与麻疹、腮腺炎、风疹和水痘相关的热性惊厥相关的安全性问题的担忧第一剂后。实施 UVV 的国家水痘发病率、住院率和并发症均有所下降，总体上产生了有益影响。针对并发症风险较高的易感个体的替代策略效果较差。本文讨论了克服障碍的方法，以使水痘作为一种真正可通过疫苗预防的疾病向前发展。
